
    
      This is a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study
      to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated
      with diabetic peripheral neuropathy.

      The study will be a 6 to 9-week study, including a 1 to 4-week (dependent on duration of
      washout period) Screening Period, followed by a 4-week double-blind, randomized,
      placebo-controlled Treatment Period, and a 1-week Follow Up Period. Subjects eligible for the
      study will randomize to receive either NYX-2925 or placebo for 4 weeks.
    
  